ZyVersa Therapeutics’ CSO, Nicholas A. LaBella, Jr., to Present at the 3rd Annual Chronic Kidney Disease Drug Development Summit Being Held Virtually March 2-4, 2021
WESTON, Fla., Feb. 26, 2021 /PRNewswire/ — ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Nicholas A. LaBella, Jr., Chief Scientific…
Comments Off on ZyVersa Therapeutics’ CSO, Nicholas A. LaBella, Jr., to Present at the 3rd Annual Chronic Kidney Disease Drug Development Summit Being Held Virtually March 2-4, 2021